Article Text

Download PDFPDF
News and updates from
  1. Andrew Wilcock1 and
  2. Sarah Charlesworth2
  1. 1Department of Palliative Medicine, University of Nottingham, Nottingham, UK
  2., Hayward House Study Centre, Nottingham, UK
  1. Correspondence to Andrew Wilcock, Department of Palliative Medicine, University of Nottingham, Hayward House, Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK; andrew.wilcock{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. has provided essential independent information about drugs used in palliative and hospice care for over a decade. It contains the online Palliative Care Formulary, and provides free access to a Bulletin Board to stimulate questions and share experiences, a Document Library containing 475 items of useful information and a Syringe Driver Survey Database containing details of over 2350 different drug combinations. Territory-specific book versions (the UK Palliative Care Formulary, fourth edition, Hospice and Palliative Care Formulary USA, second edition and Palliative Care Formulary Canadian edition) and an ebook PDF version of the Palliative Care Formulary (PCF) can also be purchased via the website. This feature provides a selection of items which have featured in the News and Latest Additions sections in recent months; for additional information please register for free on the website.

Safety updates

Carbamazepine, oxcarbazepine and eslicarbazepine risk of serious skin reactions

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has highlighted the risk of serious skin reactions, including Stevens-Johnson syndrome, with carbamazepine, oxcarbazepine and eslicarbazepine in patients with European descent or Japanese origin who have the HLA-A*3101 genetic marker. The risk of serious skin reactions with these drugs is already known to be associated with patients of Asian origin who have the genetic marker HLA-B*1502, and screening is recommended for patients of Han Chinese or Thai origin before treatment with these drugs.

There are currently insufficient data to support screening for the HLA-A*3101 genetic marker before treatment. Current advice is that …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.